ARS Pharmaceuticals, Inc. Research And Development Expense

Quick Answer

ARS Pharmaceuticals, Inc. reported Research And Development Expense of $13.18 million for the year ending 2025.

  • ARS Pharmaceuticals, Inc. showed a decrease of -32.7% in Research And Development Expense from 2024 to 2025.
  • This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), ARS Pharmaceuticals, Inc.'s Research And Development Expense has declined by 46.4%.
  • Historical annual values: Fiscal year 2025: $13.18 million | Fiscal year 2024: $19.58 million | Fiscal year 2023: $20.27 million | Fiscal year 2022: $18.38 million | Fiscal year 2021: $20.27 million | Fiscal year 2020: $24.58 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: